跳至主要内容
临床试验/IRCT20230125057221N1
IRCT20230125057221N1招募中3 期

Assessment of the efficacy of lisdexamfetamine on fatigue in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled study

Tehran University of Medical Sciences0 个研究点目标入组 52 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
52

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 45 years(—)
性别
All

入选标准

  • Definitive diagnosis of MS based on 2017 McDonald criteria
  • Age 18 to 45 years
  • Informed and written consent of the patient
  • Total score obtained from MFIS greater than 33
  • Not changing the type or dose of DMT in the last three months

排除标准

  • Pregnancy or breastfeeding
  • Allergy to the drug or formulation ingredients
  • Severe renal failure (ClCr < 30 ml/min/1.73m2)
  • moderate to severe liver failure (Child Pugh B, C)
  • history of attack or receiving pulse dose of corticosteroid in the last one month or during the study
  • Changing the used medication during the study
  • Abuse of alcohol and drugs such as opium or psychoactive agents
  • simultaneous use or last two weeks use of amantadine, modafinil, methylphenidate, dexamphetamine
  • suffering from any untreated thyroid disorder (TSH outside the normal range)
  • Vitamin D level less than 20 ng/ml
  • A patient with anemia (hemoglobin less than 14 g/dL in men or less than 12 g/dL in women)
  • Patients who suffer from severe fatigue and need symptomatic treatment due to ethical considerations
  • History of cardiovascular or cerebrovascular disease such as IHD, ACS, heart failure, any cerebral ischemia and bleeding, and uncontrolled blood pressure (SBP =160 or DBP =100)
  • Concurrently suffering from any anxiety disorder, severe depression or psychosis for which they are receiving pharmacotherapy
  • History or simultaneous suffering from epilepsy
  • Taking monoamine oxidase inhibitors in the last 14 days

研究者

相似试验